EFG International AG Buys Shares of 40,501 Protagonist Therapeutics, Inc. $PTGX

EFG International AG purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 40,501 shares of the company's stock, valued at approximately $4,963,000. EFG International AG owned about 0.06% of Protagonist Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. acquired a new position in Protagonist Therapeutics in the 2nd quarter valued at $1,263,535,000. Johnson & Johnson acquired a new stake in shares of Protagonist Therapeutics during the second quarter worth $300,220,852,000. Janus Henderson Group PLC boosted its holdings in shares of Protagonist Therapeutics by 140.7% during the fourth quarter. Janus Henderson Group PLC now owns 2,649,981 shares of the company's stock worth $231,355,000 after purchasing an additional 1,549,160 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Protagonist Therapeutics by 66.2% in the fourth quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company's stock valued at $276,992,000 after purchasing an additional 1,262,977 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Protagonist Therapeutics by 27.2% in the fourth quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company's stock valued at $472,832,000 after purchasing an additional 1,156,461 shares during the period. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Protagonist Therapeutics Price Performance

Shares of NASDAQ:PTGX opened at $150.59 on Wednesday. The firm has a market capitalization of $9.74 billion, a PE ratio of 146.21 and a beta of 1.78. The business has a 50-day moving average of $136.34 and a two-hundred day moving average of $111.31. Protagonist Therapeutics, Inc. has a 12 month low of $54.50 and a 12 month high of $160.81.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.02. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%.The business had revenue of $213.47 million for the quarter, compared to analyst estimates of $212.03 million. Protagonist Therapeutics's quarterly revenue was up 3746.8% compared to the same quarter last year. As a group, research analysts anticipate that Protagonist Therapeutics, Inc. will post 4.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Wolfe Research started coverage on Protagonist Therapeutics in a research report on Thursday, May 21st. They set an "outperform" rating and a $135.00 target price on the stock. Citizens Jmp lifted their price target on Protagonist Therapeutics from $120.00 to $137.00 and gave the company a "market outperform" rating in a report on Wednesday, May 6th. Citigroup upped their price objective on shares of Protagonist Therapeutics from $130.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Weiss Ratings upgraded shares of Protagonist Therapeutics from a "sell (d+)" rating to a "hold (c+)" rating in a report on Tuesday, August 11th. Finally, Johnson Rice set a $165.00 target price on shares of Protagonist Therapeutics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Protagonist Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $140.53.

Insider Buying and Selling

In related news, CEO Dinesh V. Ph D. Patel sold 34,239 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $148.52, for a total value of $5,085,176.28. Following the transaction, the chief executive officer owned 523,478 shares in the company, valued at approximately $77,746,952.56. This trade represents a 6.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William D. Waddill sold 9,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the transaction, the director directly owned 7,825 shares in the company, valued at approximately $922,880.50. This trade represents a 53.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 127,000 shares of company stock valued at $17,818,139. Corporate insiders own 5.19% of the company's stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc NASDAQ: PTGX is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.

Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source